Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver Cancer

Other illness

• Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable; for example:
  • Patients on life support or in a critical care unit
  • Patients with unstable occlusive disease (e.g., crescendo angina)
  • Patients with clinically unstable cardiac arrhythmias, such as recurrent ventricular tachycardia
  • Patients with uncontrolled congestive heart failure (New York heart Association \[NYHA\] class IV)
• Patients with recent cerebral hemorrhage
• Patients with known hypersensitivity to perflutren
• Patients with known cardiac shunts
• Patients with known congenital heart defects
• Patients with severe emphysema, pulmonary vasculitis, or a history of pulmonary embolism
• Patients with respiratory distress syndrome
• Patients with a history of bleeding disorders

Lab values

• Patients with known sensitivities to albumin, blood, or blood products
• Patients with bilirubin levels \> 2 mg/dL

Other

• Females who are pregnant or nursing

• Be scheduled for sub-lobar radioembolization therapy of a previously untreated HCC mass \< 6 cm visible on grayscale ultrasound
• Be medically stable
• If a female of child-bearing age, have a negative pregnancy test prior to each ultrasound exam
• Have signed informed consent to participate in the study